3 results
* To assess the safety and tolerability of inhaled PA101 delivered via eFlow in patients with IPF with refractory chronic cough.* To assess the efficacy potential of inhaled PA101 by measuring the changes in cough severity and the urge-to-cough as…
To demonstrate that lorlatinib as a single agent (Arm A) is superior to crizotinib alone (Arm B) in prolonging Progression-Free Survival (PFS) in advanced ALK-positive NSCLC participants who are treatment naive.
The primary objective of the VertiGO! trial is to assess the feasibility of restoring vestibular function by making use of prolonged VI stimulation. This will be done using a combined VI and CI device: The CVI. To achieve this objective, patients…